313 related articles for article (PubMed ID: 37400647)
1. The place of new antibiotics for Gram-negative bacterial infections in intensive care: report of a consensus conference.
Dequin PF; Aubron C; Faure H; Garot D; Guillot M; Hamzaoui O; Lemiale V; Maizel J; Mootien JY; Osman D; Simon M; Thille AW; Vinsonneau C; Kuteifan K
Ann Intensive Care; 2023 Jul; 13(1):59. PubMed ID: 37400647
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
3. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Danjean M; Hobson CA; Gits-Muselli M; Courroux C; Monjault A; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2022 Nov; 28(11):1503.e1-1503.e3. PubMed ID: 35777602
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.
Bonnin RA; Bernabeu S; Emeraud C; Creton E; Vanparis O; Naas T; Jousset AB; Dortet L
Int J Antimicrob Agents; 2022 Oct; 60(4):106660. PubMed ID: 35988666
[TBL] [Abstract][Full Text] [Related]
6. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
Bader MS; Loeb M; Leto D; Brooks AA
Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L
Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303
[TBL] [Abstract][Full Text] [Related]
8. New β-Lactam-β-Lactamase Inhibitor Combinations.
Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
10. What to Do with the New Antibiotics?
Chaïbi K; Jaureguy F; Do Rego H; Ruiz P; Mory C; El Helali N; Mrabet S; Mizrahi A; Zahar JR; Pilmis B
Antibiotics (Basel); 2023 Mar; 12(4):. PubMed ID: 37107016
[TBL] [Abstract][Full Text] [Related]
11. Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams.
Gatti M; Pea F
Expert Rev Anti Infect Ther; 2023 Feb; 21(2):149-166. PubMed ID: 36655779
[TBL] [Abstract][Full Text] [Related]
12. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria.
Yusuf E; Bax HI; Verkaik NJ; van Westreenen M
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33806604
[TBL] [Abstract][Full Text] [Related]
13.
Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors.
Gatti M; Pea F
Expert Rev Clin Pharmacol; 2021 May; 14(5):583-599. PubMed ID: 33687300
[TBL] [Abstract][Full Text] [Related]
15. Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target
Hayden DA; White BP; Bennett KK
J Pharm Technol; 2020 Oct; 36(5):202-210. PubMed ID: 34752560
[No Abstract] [Full Text] [Related]
16. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
[TBL] [Abstract][Full Text] [Related]
17. Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians.
Principe L; Lupia T; Andriani L; Campanile F; Carcione D; Corcione S; De Rosa FG; Luzzati R; Stroffolini G; Steyde M; Decorti G; Di Bella S
Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455461
[TBL] [Abstract][Full Text] [Related]
18. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
[TBL] [Abstract][Full Text] [Related]
19. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
[TBL] [Abstract][Full Text] [Related]
20. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
Wright H; Bonomo RA; Paterson DL
Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
